Inventiva (IVA) Cash & Equivalents (2018 - 2025)
Inventiva (IVA) posted quarterly Cash & Equivalents of $115.6 million for Q4 2025, up 11.99% year-over-year from $103.2 million in Q4 2024, and down 16.34% quarter-over-quarter from $138.2 million in Q2 2025.
Analysis
Inventiva (IVA) Cash & Equivalents (2018 - 2025) Analysis & Trends
Inventiva's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $115.6 million for Q4 2025.
- In Q4 2025, Cash & Equivalents rose 11.99% year-over-year to $115.6 million; the TTM figure through Dec 2025 stood at $115.6 million (up 11.99% YoY), while the FY2025 annual figure was $115.6 million, up 11.99% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $115.6 million, down from $138.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $138.2 million in Q2 2025, with the low at $10.9 million in Q2 2024.
- The 5-year median for Cash & Equivalents is $93.8 million (2021), against an average of $79.6 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 67.88% in 2024, then jumped 1164.6% in 2025.
- Inventiva's Cash & Equivalents stood at $99.0 million in 2021, then declined by 10.63% to $88.5 million in 2022, then plunged by 67.27% to $29.0 million in 2023, then soared by 256.42% to $103.2 million in 2024, then increased by 11.99% to $115.6 million in 2025.
- Business Quant data shows IVA's Cash & Equivalents at $115.6 million in Q4 2025, $138.2 million in Q2 2025, and $103.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | 115.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 115.60 Mn |
| Jun 30, 2025 | 138.19 Mn |
| Dec 31, 2024 | 103.19 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Dec 31, 2023 | 28.96 Mn |
| Jun 30, 2023 | 34.02 Mn |
| Dec 31, 2022 | 88.49 Mn |
| Jun 30, 2022 | 81.53 Mn |
| Dec 31, 2021 | 99.01 Mn |
| Jun 30, 2021 | 112.76 Mn |
| Mar 31, 2021 | 130.04 Mn |
| Dec 31, 2020 | 126.01 Mn |
| Jun 30, 2020 | 57.58 Mn |
| Dec 31, 2019 | 39.67 Mn |
| Dec 31, 2018 | 64.71 Mn |